Press Release
▪ A model of Indo–French collaboration to deliver high-quality therapies
▪ Investing around €15 million euro in 2026 to set up a platform and work with Indian partners to develop top quality Single Pill Combinations (SPCs) to be exported from India to several countries where the unmet need of patient adherence is high.
Mumbai, India February 10, 2026: Servier, the independent French pharmaceutical group governed by a foundation, has announced the establishment of a global platform in India – ‘GATINN’ – to work with partners to develop, manufacture and export Single Pill Combinations (SPCs)1
1 A SPC is a combination of several active ingredients in a single pill and facilitates treatment adherence for patients with chronic diseases which otherwise entail a multiple pills treatment. for cardiometabolic and venous diseases. The platform aims to improve adherence and enable better long-term outcomes for patients globally by simplifying treatment regimens through SPCs. The initiative reflects Servier’s 2030 ambition to accelerate innovation and deliver patient-centric solutions, particularly in chronic conditions where treatment adherence remains a critical challenge.
Elaborating on this, Dr. Kshitij Panse, Chief Operating Officer – GATINN, said, “GATINN embodies Servier’s strategy to address critical patient unmet needs by accelerating patient-centric innovation. ‘GATI’ signifies speed, reflecting our focus on rapidly delivering solutions, while ‘INN’ represents innovation in India. By combining a dedicated local team, carefully selected partners, and Servier’s global R&D, manufacturing, and quality expertise, we are building a platform to execute high-quality SPCs that meet global standards and help improve adherence and outcomes for patients worldwide.”
Servier plans to invest approximately €15 million in 2026 in GATINN, working closely with Indian partners to bring high-quality, differentiated SPCs to patients. The GATINN platform integrates development, manufacturing, supply chain and quality oversight under a single India-based coordination hub. Manufacturing is carried out through selected Indian CDMO partners, while active pharmaceutical ingredients continue to be sourced from Servier’s production facilities where Servier is the originator.
This approach demonstrates a pragmatic model of Indo–French collaboration combining French R&D expertise with India’s proven development and manufacturing quality and operational agility, enabling Servier to deliver high-quality therapies with speed, cost-efficiency to multiple international markets in Asia, Latin America, Africa, and the Middle East regions. Press Release
Speaking about the platform, Ms. Charlotte Marmousez, Executive Vice President Corporate Strategy & Transformation, said, “The decision to establish GATINN in India aligns with Servier’s global strategy to advance patient-centered innovation by developing top quality SPCs to improve patient adherence. This is first such platform for Servier, which will coordinate on behalf of the global Servier teams from research and manufacturing, based in the headquarters in France.”
Few projects have already been initiated with the first international launch expected in Q2 2027. The platform is expected to have around 5 products in development by the end of 2026, followed by the addition of approximately one new SPC each year till 2030—thereby establishing a steady pipeline of SPCs
About Servier India
Servier India is a leading healthcare company committed to transforming lives by delivering advanced, high-quality medicines that address evolving patient needs and drive impactful health outcomes. With a strong presence for around four decades in India, our focus spans key therapeutic areas – cardiometabolism, venous diseases and oncology. As part of Servier group operating in more than 130 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation.
About Servier
Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.
More information on the Group website: servier.com
Follow us on social media: LinkedIn, Facebook, X, Instagram
Press contacts
Priya Panwekar
Email: priya.panwekar@servier.com
Tel: +91 70456 54080
Aniket Singh Saran
Email: Aniket@avianwe.com
Tel: +91 9560476715 Press Release
Additional Quotes:
Dr. Philippe Gonnard, Executive Vice President Global Product Strategy, said, “At Servier, our purpose is to advance therapeutic progress that truly meets patient needs. GATINN reflects this long-term, patient-centric approach—building capabilities where they create the greatest patient value, improve adherence, while empowering global teams to deliver meaningful impact worldwide.”
Mr. Stéphane Mascarau, Executive Vice President World Operations, said, “Servier Operations teams are working to ensure that these SPCs developed in India are rapidly made available for patients particularly across Asia, Latin America, Middle East and Africa thereby answering the unmet patient need of adherence to treatment.”
Mr. Aurelien Breton, Managing Director, Servier India said, “GATINN not only builds local capabilities, but also reinforces our long-term commitment to India and strengthens our presence in the country.”
